Evotec SE announced recently that the company received a €3 million milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into phase-II clinical development as a potential treatment for Diabetic Neuropathic Pain (DNP), Evotec notified in a statement.
BAY 2395840 is an investigational oral antagonist of the bradykinin receptor B1 (BDKRB1), which is known to play a role in pain perception, the statement further said.
Bayer has initiated a phase-II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo. The phase-II study is anticipated to run until the end of 2022, added the statement.